Eli Lilly has released data showing ineffective drug pricing hikes in 2016. The pharmaceutical manufacturer raised drug prices an estimated 14% last year, but only gained 2.4% in returns. In comparison, a 16.3% hike yielded a 9.4% rise. The company has cited payer discounts as a possible reason for the dwindling numbers, as the average discount amounts to nearly 50% of the overall drug price. Read the full article here.